Take a look at our year as told by the numbers to see a snapshot of the breakthrough scientific discoveries and important work happening at CCR.
- 234Open Clinical Trials
- 45New Clinical Trials
- 1,547New Patients
- 236Principal Investigators
- 11New Faculty Recruits
- 7Newly Tenured Investigators
- 345Staff Scientists/Staff Clinicians
- ~500Technical Lab Staff
- ~800Postdoctoral/Clinical Fellows
- 327Postbaccalaureate/Predoctoral Students
- >1,000Articles in Peer-Reviewed Journals
- 47Technology Facilities and Platforms
Technology Transfer Activities
- 70New Employee Invention Reports
- 61Issued U.S. Patents
- 28New Cooperative Research and Development Agreements (CRADAs)
- 7New Clinical CRADAs
- 183Active CRADAs
- 87Clinical CRADAs
- 9Umbrella CRADAs
- 17New Clinical Trial Agreements (CTAs)
- 88Active CTAs
- 110New Licenses for CCR Technologies
- 559Active Licenses
- 2FDA Approvals
- 1FDA Breakthrough Drug Designation
- 1FDA Orphan Drug Designation
The NCI Technology Transfer Center (TTC) works to enable and guide collaboration, invention development and licensing to advance today’s discoveries into tomorrow’s medical care. The TTC supports technology development activities for NCI in therapeutics, diagnostics, research tools, vaccines, devices and software, and facilitates partnerships with outside organizations so that NCI discoveries can reach the public in a timely manner.
For information on licensing and co-development opportunities, contact the TTC Invention Development and Marketing Unit (ncitechtransfer@mail.nih.gov), or visit techtransfer.cancer.gov for more information. Numbers are for FY2020.